Cardiomyocytes - Sarcomeres

CardiotoxicityCCCA Technology

The Problem: 
Inconsistent Cardiotoxicity Screening Process

  • The current cardiotoxicity assay does not accurately predict human cardiac toxicities
  • Some drugs do not get picked up by this assay, but do cause cardiac toxicity in humans
  • Other drugs fail in this assay but cause no cardiac side effects in humans
  • This could prevent the introduction of major new therapies
  • The FDA is considering new safety screening tools

The Solution:
Cardio Verification Test (CardioVT™)

  • 96-well format (fits in standard workflows)
  • Monitor calcium transients with fluorescent dye and high content imager
  • Human cardiomyocytes are networked and beat spontaneously or can be electrically paced
  • Addresses all cardiomyocyte biology, including connections between cells
  • CardioVT™ cell adherence technology permits sample well "flex", allowing cardiac tissue to beat in a healthy, stress free phenotype.


Latest News

New Company Formed for Development of new cardiac toxicity assays

San Diego, Calif., November 12, 2011 – Three entrepreneurs have joined to form a new company called TissueNetix, Inc., based in San Diego, CA.  The long-term goal of TissueNetix is to develop high-throughput assays based on human cellular networks.  The first assay that the company is targeting will detect compounds in the drug discovery process that have cardiac toxicity.  The founders are David Giegel, Ph.D., Roberta Gottlieb, M.D., and Lewis Shuster, M.B.A.

Go to top